



To whom it may concern

Dr. Gabriele Müller
Director Quality MEGGLE USA

Date of issue: 02.02.2021
Page 1/1
Doc.-No. EIP-0060 -USA
Revision 2

Melamine

FDA Guidance for Industry: Pharmaceutical Components at Risk for Melamine Contamination

MEGGLE Products:

- Lactose Monohydrate (USP-NF / Ph. Eur. / JP): GranuLac® 70 US, GranuLac® 140 US, GranuLac® 200 US
- Anhydrous Lactose (USP-NF / Ph. Eur. / JP): DuraLac® H

The products are lactose.

They are not covered by the definition for an “at-risk component” as referenced in footnote 3 of the FDA Guidance for Industry. On the other side Lactose is listed as an example of an “at-risk pharmaceutical component” as “sourced starting material can be derived from milk”.

Any addition of melamine would lead to OOS-results. In this respect there is no motivation to add melamine to the products.

Nevertheless, a monitoring program for melamine and cyanuric acid is implemented.

Testing is performed by an independent laboratory using the following method:

Liquid Chromatography/Tandem Mass Spectrometry (LC-MS-MS).

Detection limit melamine: 0.05 mg/kg. Detection limit cyanuric acid: 0.5 mg/kg.

Melamine and cyanuric acid are not detectable in the product.

Best regards

MEGGLE USA inc.



Dr. Gabriele Müller